Veracyte, Inc. (VCYT) key performance indicators and operating metrics (16 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Product Revenue | 3.7M | FY2026-Q1 |
| Testing Revenue | 135.1M | FY2026-Q1 |
| Gross Margin (Non-Generally Accepted Accounting Principles) | 76.00 percent | FY2026-Q1 |
| Adjusted Earnings before Interest, Taxes, Depreciation and Amortization | 42.8M | FY2026-Q1 |
| Gross Margin (Generally Accepted Accounting Principles) | 73.00 percent | FY2026-Q1 |
| Testing Volume | 45.25K | FY2026-Q1 |
| Total Volume | 47.62K | FY2026-Q1 |
| Adjusted Earnings before Interest, Taxes, Depreciation and Amortization Margin | 30.80 percent | FY2026-Q1 |
| Affirma Revenue | 46.4M | FY2026-Q1 |
| Decipher Revenue | 86.5M | FY2026-Q1 |
| Decipher Testing Volume | 28K | FY2026-Q1 |
| Biopharmaceutical and Other Revenue | 1M | FY2025-Q4 |
| Operating Expenses (Non-Generally Accepted Accounting Principles) | 65.13M | FY2025-Q4 |
| Total Test Volume | 44.97K | FY2025-Q2 |
Back to VCYT overview · VCYT earnings · VCYT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.